参考文献/References:
[1]Yu Y,Zhang H,Li X,et al.The China Patient-centered Evaluative Assessment of Cardiac Events(China PEACE)retrospective heart failure study design[J].BMJ Open,2018,8(5):e020-e918. [2]Virani SS,Alonso A,Benjamin EJ,et al.Heart Disease and Stroke Statistics-2020 Update:A Report From the American Heart Association[J].Circulation,2020,141(9): e139-e596. [3]中华医学会心血管病学分会心力衰竭学组,中国医师协会心力衰竭专业委员会,中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心力衰竭和心肌病杂志,2018,2(4):196-225. [4]吕守荣.抗心力衰竭治疗对扩张型心肌病患者临床疗效、血浆NT-proBNP及CA125的影响研究[J].中国医药指南,2019,17(35):106-107. [5]李颖.血管紧张素受体-脑啡肽酶双重抑制通过调控TGF-β/Smad信号通路对心肾综合征的作用及机制研究[D].天津医科大学,2019. [6]Chen CH.Critical Questions about PARADIGM-HF and the Future[J].Acta Cardiologica Sinica,2016,32(4):387-396. [7]Balakumar P,Sambathkumar R,Mahadevan N,et al.A potential role of the renin-angiotensin-aldosterone system in epithelial-to-mesenchymal transition-induced renal abnormalities:Mechanisms and therapeutic implications[J].Pharmacological Research,2019(146):104314. [8]Kerst AJFA.Eplerenone in patients with systolic heart failure and mild symptoms[J].Geneesmiddelenbulletin,2011,45(4):45-46. [9]McMurray JJ,Packer M,Desai AS,et al.Angiotensin-neprilysin inhibition versus enalapril in heart failure[J].N Engl J Med,2014,371(11):993-1004. [10]Zile MR,Claggett BL,Prescott MF,et al.Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients With Heart Failure[J].Journal of the American College of Cardiology,2016,68(22):2425-2436. [11]Morillas-Climent H,Seller-Moya J,Alvaro Vicedo-López,et al.Evolution of functional class,biochemical and echocardiographic parameters and clinical outcomes after sacubitril/valsartan initiation in daily practice[J].Journal of Comparative Effectiveness Research,2019,8(9):685-697. [12]李文波.沙库巴曲缬沙坦钠治疗慢性心力衰竭的效果[J].中国当代医药,2020,27(3):91-93. [13]Januzzi JL,Camacho A,Ileana LP,et al.Reverse Cardiac Remodeling and Outcome After Initiation of Sacubitril/Valsartan[J].Circulation Heart Failure,2020,13(6):e006946. [14]Velazquez EJ,Morrow DA,DeVore AD,et al.Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure[J].N Engl J Med,2019,380(6):539-548. [15]Tromp J,Khan MAF,Mentz RJ,et al.Biomarker Profiles of Acute Heart Failure Patients With a Mid-Range Ejection Fraction[J].JACC:Heart Failure,2017,5(7):507-517. [16]Garg N,Senthilkumar A,Nusair MB,et al.Heart failure with a normal left ventricular ejection fraction:epidemiology,pathophysiology,diagnosis and management[J].American Journal of the Medical Sciences,2013,346(2):129-136. [17]Jnne PA,Mann H,Ghiorghiu D.Study Design and Rationale for a Randomized,Placebo-Controlled,Double-Blind Study to Assess the Efficacy and Safety of Selumetinib in Combination With Docetaxel as Second-Line Treatment in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer(SELECT-1)-ScienceDirect[J].Clinical Lung Cancer,2016,17(2):e1-e4. [18]Voors AA,Gori M,Liu LCY,et al.Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction[J].European Journal of Heart Failure,2015,17(5):510-517. [19]Cunningham JW,Claggett BL,O’Meara E,et al.Effect of Sacubitril/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients With HFpEF[J].Journal of the American College of Cardiology,2020,76(5):503-514. [20]石宇杰,王剑飞,韩运峰,等.沙库巴曲缬沙坦治疗射血分数保留心功能衰竭的疗效研究[J].中国循证心血管医学杂志,2020,12(1):83-86. [21]胡小露,吕洋波,周亚峰,等.射血分数中间值心力衰竭住院患者的临床特征与预后分析[J].同济大学学报(医学版),2019,40(6):834-840. [22]陈存芳,贾博,江珊,等.沙库巴曲缬沙坦治疗射血分数中间值心力衰竭患者的疗效及预后[J].中国新药与临床杂志,2020,39(2):88-92. [23]Albert NM,Swindle JP,Buysman EK,et al.Lower Hospitalization and Healthcare Costs With Sacubitril/Valsartan Versus Angiotensin-Converting Enzyme Inhibitor or Angiotensin-Receptor Blocker in a Retrospective Analysis of Patients With Heart Failure[J].Journal of the American Heart Association,2019,8(9):e011089. [24]蒲军亮,张婷.沙库巴曲缬沙坦钠片联合琥珀酸美托洛尔缓释片治疗慢性心力衰竭的疗效观察[J].医学信息,2020,33(14):159-160. [25]Schwartz RG,Mckenzie WB,Alexander J,et al.Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy[J].American Journal of Medicine,1987,82(6):1109-1118.
相似文献/References:
[1]郭俊林,张立.BNP对CRT后期疗效的临床评价[J].医学信息,2018,31(01):67.[doi:10.3969/j.issn.1006-1959.2018.01.024]
GUO Jun-lin,ZHANG li.Clinical Evaluation of BNP in Treatment of Late CRT[J].Medical Information,2018,31(01):67.[doi:10.3969/j.issn.1006-1959.2018.01.024]
[2]程 林.重组人脑利钠肽用于重症急性心肌炎伴
心力衰竭患者治疗的临床研究[J].医学信息,2018,31(08):126.[doi:10.3969/j.issn.1006-1959.2018.08.042]
CHENG Lin.Clinical Study of Recombinant Human Brain Natriuretic Peptide in the Treatment of Patients with Severe Acute Myocarditis and Heart Failure[J].Medical Information,2018,31(01):126.[doi:10.3969/j.issn.1006-1959.2018.08.042]
[3]胡丽君.螺内酯联合曲美他嗪治疗慢性心力衰竭的疗效分析[J].医学信息,2018,31(08):131.[doi:10.3969/j.issn.1006-1959.2018.08.044]
HU Li-jun.Efficacy of Spironolactone Combined with Trimetazidine in the Treatment of Chronic Heart Failure[J].Medical Information,2018,31(01):131.[doi:10.3969/j.issn.1006-1959.2018.08.044]
[4]李 铎,王建华.盐酸曲美他嗪片辅助治疗对冠心病伴心力衰竭患者氧化应激、心肌功能的影响[J].医学信息,2018,31(10):126.[doi:10.3969/j.issn.1006-1959.2018.10.041]
LI Duo,WANG Jian-hua.Effect of Trimetazidine Hydrochloride Tablets Adjuvant Therapy on Oxidative Stress and Myocardial Function in Patients with Coronary Heart Disease Complicated with Heart Failure[J].Medical Information,2018,31(01):126.[doi:10.3969/j.issn.1006-1959.2018.10.041]
[5]平兰芝,黄小楼,胡天俊,等.CaMKⅡ在心血管疾病中的研究[J].医学信息,2022,35(10):59.[doi:10.3969/j.issn.1006-1959.2022.10.014]
PING Lan-zhi,HUANG Xiao-lou,HU Tian-jun,et al.Research on the Role of CaMKⅡ in Cardiovascular Diseases[J].Medical Information,2022,35(01):59.[doi:10.3969/j.issn.1006-1959.2022.10.014]
[6]刘革铭,马洪俊,刘 毅,等.心力衰竭的机制及诊疗的研究[J].医学信息,2022,35(10):91.[doi:10.3969/j.issn.1006-1959.2022.10.022]
LIU Ge-ming,MA Hong-jun,LIU Yi,et al.Mechanism, Diagnosis and Treatment of Heart Failure[J].Medical Information,2022,35(01):91.[doi:10.3969/j.issn.1006-1959.2022.10.022]
[7]黄光明,赵兴昌,符显昭.水中运动联合中药内治对糖尿病大鼠心肌细胞凋亡和心功能的影响[J].医学信息,2022,35(11):72.[doi:10.3969/j.issn.1006-1959.2022.11.020]
HUANG Guang-ming,ZHAO Xing-chang,FU Xian-zhao.Effects of Aquatic Therapeutic Exercise Combined with Traditional Chinese Medicine Internal Treatment on Cardiomyocyte Apoptosis and Cardiac Function in Diabetic Rats[J].Medical Information,2022,35(01):72.[doi:10.3969/j.issn.1006-1959.2022.11.020]
[8]何玲玲,程淑芬.曲美他嗪联合琥珀酸美托洛尔治疗冠心病心力衰竭疗效观察[J].医学信息,2018,31(13):142.[doi:10.3969/j.issn.1006-1959.2018.13.042]
HE Ling-ling,CHENG Shu-fen.Therapeutic Effect of Trimetazidine Combined with Metoprolol Succinate in the Treatment of Coronary Heart Disease with Heart Failure[J].Medical Information,2018,31(01):142.[doi:10.3969/j.issn.1006-1959.2018.13.042]
[9]赵 维,廖荣宏,王爱华.糖皮质激素治疗心力衰竭疗效与安全性的Meta分析[J].医学信息,2018,31(14):70.[doi:10.3969/j.issn.1006-1959.2018.14.021]
ZHAO Wei,LIAO Rong-hong,WANG Ai-hua.Meta-analysis of the Efficacy and Safety of Glucocorticoids in the Treatment of Heart Failure[J].Medical Information,2018,31(01):70.[doi:10.3969/j.issn.1006-1959.2018.14.021]
[10]施国富,吴春阳,施亚明,等.血浆脑钠肽对射血分数保留心力衰竭患者的诊断价值研究[J].医学信息,2018,31(16):47.[doi:10.3969/j.issn.1006-1959.2018.16.013]
SHI Guo-fu,WU Chun-yang,SHI Ya-ming,et al.Diagnostic Value of Plasma Brain Natriuretic Peptide in Patients with Heart Failure Preserved by Ejection Fraction[J].Medical Information,2018,31(01):47.[doi:10.3969/j.issn.1006-1959.2018.16.013]
[11]李 龙,汪莲开.沙库巴曲缬沙坦在心力衰竭治疗中的应用[J].医学信息,2020,33(02):58.[doi:10.3969/j.issn.1006-1959.2020.02.016]
LI Long,WANG Lian-kai.Application of Shakubatrivasartan in the Treatment of Heart Failure[J].Medical Information,2020,33(01):58.[doi:10.3969/j.issn.1006-1959.2020.02.016]
[12]韦怡春,易秋艳.沙库巴曲缬沙坦对心力衰竭患者抑郁的影响[J].医学信息,2021,34(23):29.[doi:10.3969/j.issn.1006-1959.2021.23.008]
WEI Yi-chun,YI Qiu-yan.Effect of Sacubitril Valsartan on Depression in Patients with Heart Failure[J].Medical Information,2021,34(01):29.[doi:10.3969/j.issn.1006-1959.2021.23.008]
[13]刘文烜,胡 晋,钟小丽,等.沙库巴曲缬沙坦联合八段锦对心力衰竭合并室性心律失常的临床疗效研究[J].医学信息,2025,38(09):105.[doi:10.3969/j.issn.1006-1959.2025.09.020]
LIU Wenxuan,HU Jin,ZHONG Xiaoli,et al.Study on the Clinical Effect of Sacubitril/Valsartan Combined with Baduanjin on Heart Failure Complicated with Ventricular Arrhythmia[J].Medical Information,2025,38(01):105.[doi:10.3969/j.issn.1006-1959.2025.09.020]